Stay updated with breaking news from Jonathan Savidge. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
22 Apr 2024 Edinburgh UK, 22 April 2024 - Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine...
Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
University of Edinburgh biotechnology spinout Kynos Therapeutics Ltd has announced that dosing is underway in a first in-human phase I trial of its lead drug candidate, KNS366.
Kynos Therapeutics announces a first-in-human Phase I study of its novel small molecule KMO inhibitor, KNS366, is underwayEdinburgh UK, 18 May 2023 - Kynos Therapeutics Ltd, a biotechnology company developing a portfolio of first in class kynurenine 3-monooxygenase (KMO) inhibitors, today announces that dosing is un...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!